Premium
Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide
Author(s) -
Raptis C.,
GarciaBorreguero D.,
Weber M. M.,
Dose M.,
Bremer D.,
Emrich H. M.
Publication year - 1990
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.1990.tb06472.x
Subject(s) - haloperidol , brief psychiatric rating scale , placebo , extrapyramidal symptoms , psychopathology , rating scale , psychology , psychosis , carbamazepine , psychiatry , schizophrenia (object oriented programming) , medicine , anesthesia , antipsychotic , dopamine , epilepsy , developmental psychology , alternative medicine , pathology
A recent study showed an adjuvant effect of carbamazepine in the neuroleptic treatment of acute schizophrenic psychoses. Since beclamide (β‐chlorpropionamide) was reported to reduce the neuroleptic doses required, the combination haloperidol‐beclamide was tested using a double‐blind, placebo‐controlled study in 23 inpatients with an acute schizophrenic psychosis. In both groups patients received haloperidol and either beclamide or placebo. Every 7 d the treating psychiatrist could increase the haloperidol dose by 3 mg per day if clinically necessary. Chlorprothixene and biperiden were on hand as additional medication. After 28 d beclamide or placebo were discontinued under a constant dose of haloperidol and a final rating with the Inpatient Multidimensional Rating Scale, Brief Psychiatric Rating Scale, and Extrapyramidal Symptom Scale was carried out. Without reaching statistical significance, the beclamide group needed a lower dose of neuroleptic medication, showed fewer side effects and a more pronounced psychopathological improvement.